OBJECTIVES: To evaluate the therapeutic role of botulinum toxin injection in @entity1 with @entity1067 . METHODS: @entity1 with @entity1067 were enrolled in a randomized, placebo-controlled study. After a baseline evaluation, each @entity1 received 4 mL of solution injected into the prostate gland. @entity1 in the control group received saline solution and @entity1 in the treated group received 200 U of botulinum toxin A. The outcome of each group was evaluated by comparing the symptom scores, serum @entity1486 concentration, prostate volume, postvoid residual urine volume, and peak urinary flow rates. RESULTS: Thirty consecutive @entity1 were enrolled. No local complications or systemic side effects were observed in any @entity1 . After 2 months, 13 @entity1 in the treated group and 3 in the control group had subjective symptomatic relief (P = 0.0007). In @entity1 who received botulinum toxin, the symptom score was reduced by 65% compared with baseline values and the serum @entity1486 concentration by 51% from baseline. In @entity1 who received saline, the symptom score and serum @entity1486 concentration were not significantly changed compared with the baseline values and 1-month values. Follow-up averaged 19.6 +/- 3.8 months. CONCLUSIONS: Botulinum toxin injected into the prostate seems to be a promising approach for the treatment of @entity1067 . It is safe, effective, and well-tolerated. Furthermore, it is not related to the @entity1 's willingness to complete treatment.

Relief by botulinum toxin of voiding dysfunction due to XXXX : results of a randomized, placebo-controlled study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'participant', 'patient', 'Men', 'men'] @entity1067 :: ('MESH:D011470', 'Disease') :: ['benign prostatic hyperplasia'] @entity1486 :: ('354', 'Gene') :: ['prostate-specific antigen']
@entity1067 :: (MESH:D011470,Disease) :: ['benign prostatic hyperplasia']
